Verastem, Inc. (0LOV.L)

USD 4.46

(-3.44%)

Total Debt Summary of Verastem, Inc.

  • Verastem, Inc.'s latest annual total debt in 2023 was 41.55 Million USD , up 53.55% from previous year.
  • Verastem, Inc.'s latest quarterly total debt in 2024 Q2 was 41.86 Million USD , down -20.24% from previous quarter.
  • Verastem, Inc. reported annual total debt of 27.06 Million USD in 2022, up 1095.45% from previous year.
  • Verastem, Inc. reported annual total debt of 2.26 Million USD in 2021, down -89.96% from previous year.
  • Verastem, Inc. reported quarterly total debt of 52.48 Million USD for 2024 Q1, up 26.3% from previous quarter.
  • Verastem, Inc. reported quarterly total debt of 42.03 Million USD for 2023 Q3, down -1.08% from previous quarter.

Annual Total Debt Chart of Verastem, Inc. (2023 - 2011)

Historical Annual Total Debt of Verastem, Inc. (2023 - 2011)

Year Total Debt Total Debt Growth
2023 41.55 Million USD 53.55%
2022 27.06 Million USD 1095.45%
2021 2.26 Million USD -89.96%
2020 22.54 Million USD -79.04%
2019 107.53 Million USD -10.73%
2018 120.45 Million USD 712.33%
2017 14.82 Million USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%

Peer Total Debt Comparison of Verastem, Inc.

Name Total Debt Total Debt Difference
Editas Medicine, Inc. 36.53 Million USD -13.743%
Dynavax Technologies Corporation 256.91 Million USD 83.825%
Supernus Pharmaceuticals, Inc. 41.52 Million USD -0.072%
Perrigo Company plc 4.07 Billion USD 98.98%
Illumina, Inc. 2.26 Billion USD 98.163%
Thermo Fisher Scientific Inc. 34.91 Billion USD 99.881%
Iovance Biotherapeutics, Inc. 1 Million USD -4055.7%
Walgreens Boots Alliance, Inc. 9.55 Billion USD 99.565%
IQVIA Holdings Inc. 14.23 Billion USD 99.708%
Heron Therapeutics, Inc. 173.75 Million USD 76.083%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 98.463%
Unity Biotechnology, Inc. 26.99 Million USD -53.972%
Waters Corporation 2.35 Billion USD 98.236%
Biogen Inc. 7.33 Billion USD 99.434%
Sangamo Therapeutics, Inc. 38.1 Million USD -9.062%
Evolus, Inc. 126.54 Million USD 67.161%
Adicet Bio, Inc. 17.7 Million USD -134.746%
Cara Therapeutics, Inc. 43.16 Million USD 3.73%
bluebird bio, Inc. 330.32 Million USD 87.419%
Esperion Therapeutics, Inc. 540.94 Million USD 92.318%
FibroGen, Inc. 170.45 Million USD 75.62%
Agilent Technologies, Inc. 2.73 Billion USD 98.481%
Corbus Pharmaceuticals Holdings, Inc. 20.88 Million USD -98.987%
Homology Medicines, Inc. 44.05 Million USD 5.668%
Geron Corporation 85.89 Million USD 51.621%
Alnylam Pharmaceuticals, Inc. 2.39 Billion USD 98.267%
Amicus Therapeutics, Inc. 445.05 Million USD 90.663%
Myriad Genetics, Inc. 145 Million USD 71.34%
Viking Therapeutics, Inc. 1.26 Million USD -3198.175%
Intellia Therapeutics, Inc. 115.34 Million USD 63.972%
Zoetis Inc. 6.8 Billion USD 99.389%
Abeona Therapeutics Inc. 4.4 Million USD -844.048%
Mettler-Toledo International Inc. 2.16 Billion USD 98.083%
BioMarin Pharmaceutical Inc. 1.13 Billion USD 96.335%
Vertex Pharmaceuticals Incorporated 808.4 Million USD 94.859%
Kala Pharmaceuticals, Inc. 36.32 Million USD -14.41%
Ionis Pharmaceuticals, Inc. 1.45 Billion USD 97.141%
Atara Biotherapeutics, Inc. 57.87 Million USD 28.192%
Nektar Therapeutics 230.4 Million USD 81.963%
Axsome Therapeutics, Inc. 186.37 Million USD 77.702%
Aclaris Therapeutics, Inc. 3.07 Million USD -1251.887%
Sarepta Therapeutics, Inc. 1.39 Billion USD 97.025%
OPKO Health, Inc. 326.56 Million USD 87.274%
Exelixis, Inc. 189.94 Million USD 78.121%
Neurocrine Biosciences, Inc. 428.4 Million USD 90.299%
Corcept Therapeutics Incorporated 151 Thousand USD -27421.192%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 138.4 Million USD 69.975%
Imunon, Inc. 1.13 Million USD -3547.613%
Blueprint Medicines Corporation 774.12 Million USD 94.632%
Insmed Incorporated 1.2 Billion USD 96.548%
Halozyme Therapeutics, Inc. 1.49 Billion USD 97.228%
Agios Pharmaceuticals, Inc. 56.98 Million USD 27.078%
TG Therapeutics, Inc. 110.79 Million USD 62.492%
Incyte Corporation 38.28 Million USD -8.541%
Emergent BioSolutions Inc. 877.5 Million USD 95.264%